Patent ID: 7557183

Claim:
A PEGylated GLP-1 compound comprising the amino acid sequence of Formula IV (SEQ ID NO:6) Formula IV (SEQ ID NO: 6) Xaa 7 -Xaa 8 -Glu-Gly-Xaa 11 -Xaa 12 -Thr-Ser-Asp-Xaa 16 - Ser-Xaa 18 -Xaa 19 -Xaa 20 -Glu-Xaa 22 -Xaa 23 -Xaa 24 -Xaa 25 - Xaa 26 -Xaa 27 -Phe-Ile-Xaa 30 -Trp-Leu-Xaa 33 -Xaa- 34 - Xaa 35 -Xaa 36 -Xaa 37 -Xaa 38 -Xaa 39 -Xaa 40 -Xaa 41 -Xaa 42 - Xaa 43 -Xaa 44 -Xaa 45 -Xaa 46 -Xaa 47 wherein: Xaa 7 is: L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, α-fluoromethyl-histidine, or α-methyl-histidine; Xaa 8 is: Ala, Gly, Val, Leu, Ile, Ser, or Thr; Xaa 11 is: Thr or Cys Xaa 12 is: Phe, Trp, Tyr, or Cys; Xaa 16 is: Val, Trp, Ile, Len, Phe, Tyr, or Cys; Xaa 18 is: Ser, Trp, Tyr, Phe, Lys, Ile, Leu, Val; Xaa 19 is: Tyr, Trp, or Phe; Xaa 20 is: Leu, Phe, Tyr, or Trp; Xaa 22 is: Gly, Gln, Asp, Lys or Cys; Xaa 23 is: Gln or Cys; Xaa 24 is: Ala or Cys; Xaa 25 is: Ala, Val, Be, Leu, or Cys; Xaa 26 is: Lys or Cys; Xaa 27 is: Gln, Be, Ala, or Cys; Xaa 30 is: Ala, Gln or Cys Xaa 33 is: Val or Ile; Xaa 34 is: Lys, Asp, Arg, Glu or Cys; Xaa 35 is: Gly or Cys; Xaa 36 is: Gly, Pro, Arg or Cys; Xaa 37 is: Gly, Pro, Ser or Cys; Xaa 38 is: Ser, Pro, His or Cys; Xaa 39 is: Ser, Arg, Thr, Trp, Lys or Cys; Xaa 40 is: Ser, Gly, or Cys; Xaa 41 is: Ala, Asp, Arg, Glu, Lys, Gly, or Cys; Xaa 42 is: Pro, Ala, Cys, NH 2 , or is absent; Xaa 43 is: Pro, Ala, Cys, NH 2 , or is absent; Xaa 44 is: Pro, Ala, Arg, Lys, His, Cys, NH 2 , or is absent; Xaa 45 is: Ser, His, Pro, Lys, Arg, Cys, NH 2 or is absent; Xaa 46 is: His, Ser, Arg, Lys, Cys, NH 2 or is absent; and Xaa 47 is: His, Ser, Arg, Lys, Cys, NH 2 or is absent; and wherein: at least one Cys residue is covalently attached to a PEG molecule, and provided that if Xaa 42 , Xaa 43 , Xaa 44 , Xaa 45 or Xaa 46 is absent each amino acid downstream is absent; and provided that there are no more than two Cys residues in the molecule.